Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls

By Yoshinori Sagehashi Japan’s all-important reimbursement policy panel adopted the government’s drug pricing reform package, with a significant reduction in the scope of eligible on-patent products for the so-called price maintenance premium (PMP) . On an off-patent drug front, long-listed...read more